| 2 min read
Register for free to listen to this article
Listen with Speechify
0:00
2:00
AUSTIN, Texas—Ambion Inc., a provider of RNA analysis tools and reagents, recently announced it formalized a license and supply agreement with GE Healthcare whereby GE will manufacture for Ambion its mirVana line of microRNA (miRNA) microarrays using GE's CodeLink bioarray technology. The mirVana miRNA bioarrays include a comprehensive panel of known human, mouse and rat miRNAs as well as Ambion's proprietary, non-published microRNAs, Ambi-miRs.
 
According to Rod Klassy, business development manager for Ambion, the move to create a commercial supply of miRNA bioarrays comes as the company sees an awakening commercial market for these and associated microRNA products.
 
"MicroRNAs are relatively young in their biological discovery phase," says Klassy. "There's a lot of interest in them and we've noted that if you search the publication records you'll see a rapid increase in publications from 2003 where there were less than  a couple dozen to 400 or 500 in 2005."
 
The announcement of the deal also comes as GE actively searches for ways it can broaden the use of its CodeLink bioarray technology. "This is a great example of how we can take CodeLink's proven technology into new application areas by partnersing with companies who are leaders in their field," says Ger Brophy, VP of product acquisition and licensing for Discovery Systems, GE Healthcare, in a statement announcing the Ambion deal. "The combination of CodeLink's array technology with Ambion's content and assays creates an innovative and powerful tool that meets the needs of this growing research market."
 
Indeed, Ambion is attempting to get out ahead of the pack. Long known as an RNA specialist —it has even trademarked the term "The RNA Company"—Ambion's management anticipates the awakening interest in the field will make its miRNA line a significant revenue stream in the coming years.
 
The decision to work with GE arose from work performed by Ambion researcher Dr. David Brown, who was doing self-spotting arrays. While using what were the CodeLink blanks, Brown and his team noticed that the arrays they were spotting on the GE slides were consistently better.
 
Once Ambion chose GE,  researchers from both companies collaborated to make test slides using GE's spotting equipment as well as work with GE's informatics group for probe design.
 
Klassy also says using GE will help Ambion penetrate the miRNA research market quicker, in particular among academic researchers.
 
"The number of academic labs that want to do this research is growing rapidly and not all of them have access to Affymetrix platforms," says Klassy. "Having a CodeLink blank that can be hybridized in a normal array or slide hybridization chamber and read on any scanner was quite attractive for us simply because of the market demographics."

About the Author

Related Topics

Published In

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Clear sample tubes are shown in a clear tote with red lids in a sample prep robot with a blue and silver industrial lab background.

The crucial role of sample preparation in biotherapy manufacturing

Discover how better sample preparation can unlock improved assay accuracy and analytical results.
A black mosquito is shown on pink human skin against a blurred green backdrop.

Discovering deeper insights into malaria research

Malaria continues to drive urgent research worldwide, with new therapies and tools emerging to combat the parasite’s complex lifecycle and global burden.
Three burgundy round and linear conformations of oligonucleotides are shown against a black background.

Accelerating RNA therapeutic testing with liver microphysiological platforms

Researchers can now study oligonucleotide delivery and efficacy in a system that models a real human liver.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue